Skip to main content
Home / Die Pharmazie - An International Journal of Pharmaceutical Sciences, Volume 79, Number 6

Open Access Content loaded within last 14 days DN4 questionnaire as a useful tool for evaluating the pharmacotherapeutic response to opioid pharmacotherapy in malignant neuropathy

Download Article:
Objective: Tapentadol is a drug of choice for neuropathic cancer pain. DN4 questionnaire quickly determines neuropathic pain component. The aim of this study is to determine the correlation between neuropathic malignant pain component by applying tapentadol antidolorose pharmacotherapy in combination with palliative radiotherapy of osseous neuropathic metastatic changes in breast cancer patients before and after palliative radiotherapy. Methods: The first patients group comprised 30 patients with primary breast cancer and proved painful bone secondary deposits with neuropathy for which tapentadol was prescribed, and they underwent palliative radiotherapy. The second group comprised 30 patients with primary breast cancer and proved painful bone metastases with neuropathy treated only with palliative antidolorose radiotherapy. Key findings : After two-months-follow up, tapentadol group patients had lower DN4 score values (Z=2,021; p=0.043). Significantly lower number of tapentadol group patients was without neuropathic pain after a three-month-follow up (χ 2=5,711; p=0.017). Significantly greater number of tapentadol group patients had best ECOG score 0 ( χ2 =7,486; p=0.023). There was statistically significant positive correlation between tapentadol dose and DN4 score in patients after a month (ρ=0,471; p=0.009) and three months after the radiotherapy completion (ρ=0,610; p<0.001). Tapentadol is an opioid analgesic efficient for neuropathy relief in these patients and DN4 questionnaire is an efficient pharmacotherapy tool.

Document Type: Research Article

Affiliations: 1: Department for Pharmacology and Toxicology , Faculty of Medicine, University of Nis; Clinic for Oncology, University Clinical Center Nis 2: Department for Pharmacology and Toxicology , Faculty of Medicine, University of Nis 3: Department for Oncology , Faculty of Medicine, University of Nis; Clinic for Oncology , University Clinical Center Nis 4: Department for Oncology, Faculty of Medicine, University of Nis; Clinic for Oncology , University Clinical Center Nis 5: Department for Oncology, Faculty of Medicine, University of Nis; Clinic for Oncology, University Clinical Center Nis 6: Clinic for Oncology, University Clinical Center Nis; 7: Clinic for Oncology, University Clinical Center Nis 8: Department for Psychiatry, Faculty of Medicine, University of Nis; Clinic for Psychiatry, University Clinical Center Nis 9: Department for Medical Statistics and Informatics, Faculty of Medicine, University of Nis; Institute for Public Health Nis, Nis 10: Department for Pharmacology and Toxicology, Faculty of Medicine, University of Nis 11: Faculty of Medicine, University of Novi Sad, Novi Sad; Institute for Public Health Vojvodina, Novi Sad: 12: Faculty of Medicine, University of Novi Sad, Novi Sad; Institute of Cardiovascular Diseases Vojvodina, Sremska Kamenica 13: Clinic for Gynecology and Obstetrics, Narodni Front, Belgrade; Faculty of Medicine, University of Belgrade, Belgrade, Serbia

Publication date: June 1, 2024

More about this publication?
  • Pharmazie is a leading journal in the field of pharmaceutical sciences. As a peer-reviewed scientific journal, Pharmazie is regularly indexed in the relevant databases like Web of science, Journal Citation Reports and many others. The journal is open for submissions from the whole spectrum of pharnaceutical sciences including Pharmaceutical Chemistry, Experimental and Clinical Pharmacology, Drug Analysis, Pharmaceutics, Pharmaceutical Biology, Clinical Pharmacy etc.
  • Information for Authors
  • Submit a Paper
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites

Share Content

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
-